Literature DB >> 10958240

Guidelines and recommendations for antimicrobial minimum inhibitory concentration (MIC) testing against veterinary mycoplasma species. International Research Programme on Comparative Mycoplasmology.

P C Hannan1.   

Abstract

The absence of standardised procedures for minimum inhibitory concentration (MIC) testing of antimicrobial agents against veterinary mycoplasma and ureaplasma species (Mollicutes) has made it difficult to compare results originating from different laboratories. This report, prepared on behalf of the International Research Programme on Comparative Mycoplasmology (IRPCM), offers guidelines and recommendations for veterinary MIC testing of these organisms in an effort to rectify this problem. The subjects discussed include suitable media for broth and agar MIC assays, storage and preparation of antimicrobial agents, standardisation of mycoplasma inocula for MIC tests, validation of equipment, incubation conditions, and determination of MIC end points. A standard medium for all veterinary mycoplasma MIC tests cannot currently be recommended, owing to the diversity of nutritional requirements of different mycoplasma species. Instead mycoplasma broths or agars giving optimal growth of specific mycoplasmas or ureaplasmas are recommended, as suboptimal growth may lead to falsely low MIC results. The importance of using standardised mycoplasma inocula, for assays using either solid or liquid media is stressed. The growth phase may be less important as lag phase and logarithmic phase cultures of Mycoplasma gallisepticum, M. synoviae, M. bovis and M. hyopneumoniae have given very similar results in liquid MIC assays. The liquid method of Tanner and Wu and the agar method described by Hannan et al. are compared and described in detail. Methods for calculating MIC50s and MIC90s are described and the interpretation of results discussed. Methods for assessing mycoplasmacidal (MMC) activity of antimicrobial agents are also described. Adoption of these guidelines should lead to more consistent MIC results being obtained between laboratories.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10958240     DOI: 10.1051/vetres:2000100

Source DB:  PubMed          Journal:  Vet Res        ISSN: 0928-4249            Impact factor:   3.683


  65 in total

1.  In vitro susceptibilities of Mycoplasma hyopneumoniae field isolates.

Authors:  J Vicca; T Stakenborg; D Maes; P Butaye; J Peeters; A de Kruif; F Haesebrouck
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

2.  Rapid detection of a point mutation in the parC gene associated with decreased susceptibility to fluoroquinolones in Mycoplasma bovis.

Authors:  I Lysnyansky; I Mikula; I Gerchman; S Levisohn
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

3.  Flow cytometric determination of the effects of antibacterial agents on Mycoplasma agalactiae, Mycoplasma putrefaciens, Mycoplasma capricolum subsp. capricolum, and Mycoplasma mycoides subsp. mycoides large colony type.

Authors:  Patricia Assunção; Nuno T Antunes; Ruben S Rosales; Carlos Poveda; Jose B Poveda; Hazel M Davey
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

4.  Antibiotic susceptibility testing of Mycoplasma genitalium by TaqMan 5' nuclease real-time PCR.

Authors:  Ryoichi Hamasuna; Yukio Osada; Jørgen Skov Jensen
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  In vivo pharmacokinetic/pharmacodynamic profiles of valnemulin in an experimental intratracheal Mycoplasma gallisepticum infection model.

Authors:  Xia Xiao; Jian Sun; Tao Yang; Xi Fang; Dong Wu; Yan Q Xiong; Jie Cheng; Yi Chen; Wei Shi; Ya-Hong Liu
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

6.  A study of in vitro antibacterial activity of lanthanides complexes with a tetradentate Schiff base ligand.

Authors:  Waleed Mahmoud Al Momani; Ziyad Ahmed Taha; Abdulaziz Mahmoud Ajlouni; Qasem Mohammad Abu Shaqra; Muaz Al Zouby
Journal:  Asian Pac J Trop Biomed       Date:  2013-05

7.  Mutations Associated with Decreased Susceptibility to Seven Antimicrobial Families in Field and Laboratory-Derived Mycoplasma bovis Strains.

Authors:  Kinga M Sulyok; Zsuzsa Kreizinger; Enikő Wehmann; Inna Lysnyansky; Krisztián Bányai; Szilvia Marton; Ákos Jerzsele; Zsuzsanna Rónai; Ibolya Turcsányi; László Makrai; Szilárd Jánosi; Sára Ágnes Nagy; Miklós Gyuranecz
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

8.  Eosinophilic Fasciitis associated with Mycoplasma arginini infection.

Authors:  Pálma Silló; Dóra Pintér; Eszter Ostorházi; Mercedes Mazán; Norbert Wikonkál; Katinka Pónyai; Dmitriy V Volokhov; Vladimir E Chizhikov; Susan Szathmary; Laszlo Stipkovits; Sarolta Kárpáti
Journal:  J Clin Microbiol       Date:  2011-12-21       Impact factor: 5.948

9.  Relationship between Antimicrobial Susceptibility and Multilocus Sequence Type of Mycoplasma bovis Isolates and Development of a Method for Rapid Detection of Point Mutations Involved in Decreased Susceptibility to Macrolides, Lincosamides, Tetracyclines, and Spectinomycin.

Authors:  Eiji Hata; Takehiro Harada; Megumi Itoh
Journal:  Appl Environ Microbiol       Date:  2019-06-17       Impact factor: 4.792

10.  Molecular characterization of acquired enrofloxacin resistance in Mycoplasma synoviae field isolates.

Authors:  I Lysnyansky; I Gerchman; I Mikula; F Gobbo; S Catania; S Levisohn
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.